LINE-1 methylation in peripheral blood leukocytes and clinical characteristics and prognosis of prostate cancer patients

Yuyan Han; Junfeng Xu; Jeri Kim; Xifeng Wu; Jian Gu

doi:10.18632/oncotarget.21511

LINE-1 methylation in peripheral blood leukocytes and clinical characteristics and prognosis of prostate cancer patients

Yuyan Han, Junfeng Xu, Jeri Kim, Xifeng Wu, Jian Gu

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Global DNA methylation of long interspersed nucleotide elements (LINE-1) in leukocytes has been suggested to be a risk factor for a few cancers. There has been no report of LINE-1 methylation in leukocytes as a risk factor for aggressive prostate cancer at diagnosis and prognosis after treatments. In this study, we measured the leukocyte DNA methylation of LINE-1 in 795 PCa patients and compared the methylation levels across different clinical subgroups. We then determined the association of LINE-1 methylation in leukocytes with clinicopathological variables at diagnosis using logistic regression analysis and biochemical recurrence in patients receiving active treatments (prostatectomy and radiotherapy) using Cox proportional hazard model after adjusting for age, BMI, smoking status, pack year, D'Amico risk groups, and treatments. Overall, the DNA methylation of LINE-1 was not associated with the risk of being diagnosed with high-risk prostate cancer or the risk of biochemical recurrence upon active treatments. Future studies are warranted to investigate other types of repetitive element methylation and longitudinal changes of global methylation in relation to prostate cancer risk and prognosis.

Original language	English (US)
Pages (from-to)	94020-94027
Number of pages	8
Journal	Oncotarget
Volume	8
Issue number	55
DOIs	https://doi.org/10.18632/oncotarget.21511
State	Published - Nov 1 2017

Keywords

LINE-1
Methylation
Prognosis
Prostate cancer

ASJC Scopus subject areas

Oncology

MD Anderson CCSG core facilities

Epigenomics Profiling Core Facility

Access to Document

10.18632/oncotarget.21511

Cite this

@article{b4263fe35a1a46b2bc80cc62c3868f88,

title = "LINE-1 methylation in peripheral blood leukocytes and clinical characteristics and prognosis of prostate cancer patients",

abstract = "Global DNA methylation of long interspersed nucleotide elements (LINE-1) in leukocytes has been suggested to be a risk factor for a few cancers. There has been no report of LINE-1 methylation in leukocytes as a risk factor for aggressive prostate cancer at diagnosis and prognosis after treatments. In this study, we measured the leukocyte DNA methylation of LINE-1 in 795 PCa patients and compared the methylation levels across different clinical subgroups. We then determined the association of LINE-1 methylation in leukocytes with clinicopathological variables at diagnosis using logistic regression analysis and biochemical recurrence in patients receiving active treatments (prostatectomy and radiotherapy) using Cox proportional hazard model after adjusting for age, BMI, smoking status, pack year, D'Amico risk groups, and treatments. Overall, the DNA methylation of LINE-1 was not associated with the risk of being diagnosed with high-risk prostate cancer or the risk of biochemical recurrence upon active treatments. Future studies are warranted to investigate other types of repetitive element methylation and longitudinal changes of global methylation in relation to prostate cancer risk and prognosis.",

keywords = "LINE-1, Methylation, Prognosis, Prostate cancer",

author = "Yuyan Han and Junfeng Xu and Jeri Kim and Xifeng Wu and Jian Gu",

note = "Funding Information: This study was financially supported by an individual researcher award (RP140556) from the Cancer Prevention and Research Institute of Texas (CPRIT) to Gu J and a National Cancer Institute Specialized Program of Research Excellence (SPORE) grant (CA140388) to Wu X, Gu J and Kim J. Publisher Copyright: {\textcopyright} Han et al.",

year = "2017",

month = nov,

day = "1",

doi = "10.18632/oncotarget.21511",

language = "English (US)",

volume = "8",

pages = "94020--94027",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals",

number = "55",

}

TY - JOUR

T1 - LINE-1 methylation in peripheral blood leukocytes and clinical characteristics and prognosis of prostate cancer patients

AU - Han, Yuyan

AU - Xu, Junfeng

AU - Kim, Jeri

AU - Wu, Xifeng

AU - Gu, Jian

N1 - Funding Information: This study was financially supported by an individual researcher award (RP140556) from the Cancer Prevention and Research Institute of Texas (CPRIT) to Gu J and a National Cancer Institute Specialized Program of Research Excellence (SPORE) grant (CA140388) to Wu X, Gu J and Kim J. Publisher Copyright: © Han et al.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Global DNA methylation of long interspersed nucleotide elements (LINE-1) in leukocytes has been suggested to be a risk factor for a few cancers. There has been no report of LINE-1 methylation in leukocytes as a risk factor for aggressive prostate cancer at diagnosis and prognosis after treatments. In this study, we measured the leukocyte DNA methylation of LINE-1 in 795 PCa patients and compared the methylation levels across different clinical subgroups. We then determined the association of LINE-1 methylation in leukocytes with clinicopathological variables at diagnosis using logistic regression analysis and biochemical recurrence in patients receiving active treatments (prostatectomy and radiotherapy) using Cox proportional hazard model after adjusting for age, BMI, smoking status, pack year, D'Amico risk groups, and treatments. Overall, the DNA methylation of LINE-1 was not associated with the risk of being diagnosed with high-risk prostate cancer or the risk of biochemical recurrence upon active treatments. Future studies are warranted to investigate other types of repetitive element methylation and longitudinal changes of global methylation in relation to prostate cancer risk and prognosis.

AB - Global DNA methylation of long interspersed nucleotide elements (LINE-1) in leukocytes has been suggested to be a risk factor for a few cancers. There has been no report of LINE-1 methylation in leukocytes as a risk factor for aggressive prostate cancer at diagnosis and prognosis after treatments. In this study, we measured the leukocyte DNA methylation of LINE-1 in 795 PCa patients and compared the methylation levels across different clinical subgroups. We then determined the association of LINE-1 methylation in leukocytes with clinicopathological variables at diagnosis using logistic regression analysis and biochemical recurrence in patients receiving active treatments (prostatectomy and radiotherapy) using Cox proportional hazard model after adjusting for age, BMI, smoking status, pack year, D'Amico risk groups, and treatments. Overall, the DNA methylation of LINE-1 was not associated with the risk of being diagnosed with high-risk prostate cancer or the risk of biochemical recurrence upon active treatments. Future studies are warranted to investigate other types of repetitive element methylation and longitudinal changes of global methylation in relation to prostate cancer risk and prognosis.

KW - LINE-1

KW - Methylation

KW - Prognosis

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85032974315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032974315&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.21511

DO - 10.18632/oncotarget.21511

M3 - Article

C2 - 29212206

AN - SCOPUS:85032974315

SN - 1949-2553

VL - 8

SP - 94020

EP - 94027

JO - Oncotarget

JF - Oncotarget

IS - 55

ER -

LINE-1 methylation in peripheral blood leukocytes and clinical characteristics and prognosis of prostate cancer patients

Abstract

Keywords

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this